Due to its importance for cell viability, Mps1 has emerged as a promising target for the treatment of aggressive cancers, and several Mps1 inhibitors (Mps1i) are currently in clinical trials to treat solid tumors [32–34]. The gene discussed is TTK; the disease is cancer.